Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus Joerger and Dr. David Anderson, distinguished clinical and scientific experts, have to say about how Immunophotonics is pioneering the growing field of Interventional Immuno-Oncology (IIO) with its lead drug candidate, IP-001. To read the article, click here.